- TM Capital served as exclusive financial advisor to Metrigraphics, a portfolio company of New England Capital Partners and Clarkston Merchant Partners, in its sale to Cirtec Medical, a portfolio company of 3i Group plc (LSE:III)
- Metrigraphics is a leading manufacturer of ultra-high precision, custom micron-scale medical device components for growing markets including continuous glucose monitoring, advanced drug delivery, active medication management and life science instruments
- Cirtec Medical is a premier provider of outsourced medical device design, engineering and manufacturing
- 3i Group, with $6.4 billion of capital under management, is a U.K. investment company targeting investment opportunities across Northern Europe and North America
- Cirtec Medical’s acquisition of Metrigraphics expands its portfolio of cutting edge and technically challenging medical device components serving rapidly growing markets
Client Testimonial
Having worked with TM Capital before, we knew we could expect senior partner focus, an intensive team effort from inception through closing, and insightful advice. For the Metrigraphics transaction, we also required extensive knowledge of the medical device component sector, expertise in healthcare technology developments, and deep industry relationships. TM Capital delivered all of the critical resources to achieve an outstanding outcome for the owners, management and employees of Metrigraphics."Kevin McCafferty, Chairman, New England Capital Partners
